A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Read more about A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults Read more about Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Read more about Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin Read more about Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Read more about I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer Read more about A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing Read more about A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) Read more about To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7 Read more about Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7